-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The results of the randomized phase III clinical study Check-Mate 214 showed that in patients with advanced renal cell carcinoma (aRCC) with intermediate or poor prognostic risk of IMDC, nivolumab + ipilimumab significantly prolonged the OS of patients compared with sunitinib
The results of the randomized phase III clinical study Check-Mate 214 showed that in patients with advanced renal cell carcinoma (aRCC) with intermediate or poor prognostic risk of IMDC, nivolumab + ipilimumab significantly prolonged the OS of patients compared with sunitinib
Data analysis comes from the randomized Phase III CheckMate 214 trial, nivolumab + ipilimumab (n=550) vs sunitinib (n=546) for treatment of untreated advanced renal cell carcinoma (aRCC)
Data analysis comes from the randomized Phase III CheckMate 214 trial, nivolumab + ipilimumab (n=550) vs sunitinib (n=546) for untreated advanced renal cell carcinoma (aRCC)
Among 847 aRCC patients with intermediate or poor prognostic risk of IMDC, the 42-month OS rates in the nivolumab + ipilimumab group and sunitinib group were 52% and 39%, respectively
Among 847 aRCC patients with intermediate or poor prognostic risk of IMDC, the 42-month OS rates in the nivolumab + ipilimumab group and sunitinib group were 52% and 39%, respectively
The 42-month average TFS of non-toxic patients in the nivolumab + ipilimumab group was longer than that of non-toxic patients in the sunitinib group (TFS without TRAEs ≥3: difference, 3.
The 42-month average TFS of non-toxic patients in the nivolumab + ipilimumab group was longer than that of non-toxic patients in the sunitinib group (TFS without TRAEs ≥3: difference, 3.
Among the 249 patients with a good prognosis risk for IMDC, 70.
The results of the overall intent population are similar to those of the moderate/low risk population
The results of the overall intent population are similar to those of the moderate/low risk population
In summary, studies have shown that regardless of the risk of aRCC patients, compared with the sunitinib group, non-toxic patients treated with nivolumab + ipilimumab have longer treatment-free survival (TFS)
In summary, studies have shown that regardless of the risk of aRCC patients, compared with the sunitinib group, non-toxic patients treated with nivolumab + ipilimumab have longer treatment-free survival (TFS)
Original source:
Regan MM, Jegede OA, Mantia CM, et al.
Regan MM, Jegede OA, Mantia CM, et al.
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.
Clin Cancer Res.
2021 Nov 10.
doi: 10.
1158/1078-0432.
CCR-21-2283.
Epub ahead of print.
PMID: 34759043.
Leave a message here
